comprehensive -WSS

comprehensive

author：fashion 2025-09-02 17:43:56 - browse：56

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Why health records don't always know when patients are dead

hotspot

WSS

SEC charges former device maker CEO with $41 million fraud

Medicare Advantage beneficiaries sue Humana over algorithm use

How the first Native Hawaiian psychiatrist helped diversify medicine

FDA greenlights medical device to combat bladder issues

Kellogg’s is going to war over Mexico’s nutrition label rules

Three trends to watch in biotech in 2024

hotspot

comprehensive

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Affirmative action in medical school literally saved lives

Roche's accidental data boosts hopes for anti

New air purifier tech could be key to improving indoor air quality

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Medicare details structure of new drug price negotiation program

Grail spinoff by Illumina should end disastrous merger attempt

Tori Bowie and the unacceptable rates of Black maternal death

Keeping primary care docs in field isn't impossible, says AAFP CEO

explore

Grail spinoff by Illumina should end disastrous merger attempt

National associations that represent hospice owe an apology

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Trans patients at the end of life deserve respect and dignity

Medicare Advantage beneficiaries sue Humana over algorithm use

Carvykti CAR

focus

focus

hotspot

leisure time